Skip to Menu Skip to Search Contact Us Global Websites & Languages Skip to Content

Identifying Adventitious Agents in Cell & Gene Therapy Production

In this document we look at cell and gene therapies (CGTs), an important growth sector for the biopharmaceutical industry. The US Food and Drug Administration (FDA) has now approved several CGTs for use in humans. CGT has, however, highlighted deficiencies in traditional safety models, reinforcing the need for a holistic approach to biosafety.

Please complete the form to download your copy.

Fields marked with an asterisk (*) are mandatory.

White paper request form

Are you an SGS client?*

200 characters remaining